Investigating how aging cells and specific proteins affect bone health in type 2 diabetes
Targeting Cellular Senescence and RAGE in Type 2 Diabetes
This study is looking at how aging cells and certain harmful substances in the body might make bones weaker in people with type 2 diabetes, with the hope of finding new ways to help improve bone health and lower the risk of fractures.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11085113 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of aging cells and advanced glycation endproducts (AGEs) in contributing to bone fragility in individuals with type 2 diabetes (T2D). By using advanced techniques such as mass cytometry and transgenic mice, the study aims to explore how these factors interact and affect bone health. The goal is to identify specific cellular populations and their secretions that may lead to weakened bones in T2D patients, potentially leading to new treatment strategies. This research could provide insights into how to improve bone quality and reduce fracture risk in those affected by T2D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes who may be at risk for bone fragility.
Not a fit: Patients without type 2 diabetes or those with other unrelated bone health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve bone health and reduce fracture risk in patients with type 2 diabetes.
How similar studies have performed: While the interplay between aging cells and bone health in diabetes has been explored, this specific approach targeting senescence and RAGE is relatively novel and has not been rigorously tested.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Farr, Joshua Nicholas — University of Arizona
- Study coordinator: Farr, Joshua Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.